Increased expression of Fibrinogen-Like Protein 2 is associated with poor prognosis in patients with clear cell renal cell carcinoma

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Tang, Ming ^a   Cao, Xu ^a   Li, Peng ^a   Zhang, Kun ^a   Li, You ^a   Zheng, Quan You ^a   Li, Gui Qing ^a   Chen, Jian ^a   Xu, Gui Lian ^a   Zhang, Ke Qin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FGL2 PROTEIN, HUMAN; FIBRINOGEN; MESSENGER RNA;

APOPTOSIS; BIOLOGICAL MODEL; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY TUMOR; MALE; MAPK SIGNALING; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENAL CELL CARCINOMA;

APOPTOSIS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FIBRINOGEN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER;

EID: 85030691135     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-13149-x     Document Type: Article

References (35)

1. Zhang, D., et al. PGRMC1 Is a Novel Potential Tumor Biomarker of Human Renal Cell Carcinoma Based on Quantitative Proteomic and Integrative Biological Assessments. PloS one 12, e0170453, https://doi.org/10.1371/journal.pone.0170453 (2017).
2. Bedke, J., et al. Systemic therapy in metastatic renal cell carcinoma. World journal of urology, doi:https://doi.org/10.1007/s00345-016-1868-5 (2016).
3. Weiss, R. H. & Lin, P. Y. Kidney cancer: Identification of novel targets for therapy. Kidney Int 69, 224-232, https://doi.org/10.1038/sj.ki.5000065 (2006).
4. Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet 373, 1119-1132, https://doi.org/10.1016/S0140-6736(09)60229-4 (2009).
5. Sun, M., et al. Prognostic factors and predictive models in renal cell carcinoma: A contemporary review. European urology 60, 644-661, https://doi.org/10.1016/j.eururo.2011.06.041 (2011).
6. Frank, I., et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. The Journal of urology 168, 2395-2400, https://doi.org/10.1097/01. ju.0000035885.91935.d5 (2002).
7. Shalev, I., et al. The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C VirusInfection. Rambam Maimonides medical journal 1, e0004, https://doi.org/10.5041/RMMJ.10004 (2010).
8. Ning, Q., et al. Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection. Journal of immunology 174, 7403-7411 (2005).
9. Hu, J., et al. The Duality of Fgl2-Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. International reviews of immunology 35, 325-339, https://doi.org/10.3109/08830185.2014.956360 (2016).
10. Levy, G. A., et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. The American journal of pathology 156, 1217-1225, https://doi.org/10.1016/S0002-9440(10)64992-9 (2000).
11. Rabizadeh, E., et al. The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development. Thrombosis research 136, 118-124, https://doi.org/10.1016/j.thromres.2014.11.023 (2015).
12. Wang, M., Liu, J., Xi, D., Luo, X. & Ning, Q. Adenovirus-mediated artificial microRNA against human fibrinogen like protein 2 inhibits hepatocellular carcinoma growth. The journal of gene medicine 18, 102-111, https://doi.org/10.1002/jgm.2883 (2016).
13. Liu, Y., et al. Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis. Liver International 32, 1585-1595, https://doi.org/10.1111/j.1478-3231.2012.02865.x (2012).
14. Rabizadeh, E., et al. Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients. PloS one 9, e109648, https://doi.org/10.1371/journal.pone.0109648 (2014).
15. Pengcheng, S., et al. MicroRNA-497 suppresses renal cell carcinoma by targeting VEGFR-2 in ACHN cells. Bioscience reports 37, doi:https://doi.org/10.1042/BSR20170270 (2017).
16. Miyazaki, A., Miyake, H. & Fujisawa, M. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. Clinical & translational oncology: Official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 18, 893-900, https://doi.org/10.1007/s12094-015-1457-x (2016).
17. Yan, J., et al. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. Journal of the National Cancer Institute 107, doi:https://doi.org/10.1093/jnci/djv137 (2015).
18. Su, K., et al. Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma. World journal of gastroenterology 14, 5980-5989 (2008).
19. Shalev, I., et al. The novel CD4+ CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology 49, 387-397, https://doi.org/10.1002/hep.22684 (2009).
20. Chan, C. W., et al. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: Suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. Journal of immunology 170, 4036-4044 (2003).
21. Foerster, K., et al. The novel immunoregulatory molecule FGL2: A potential biomarker for severity of chronic hepatitis C virus infection. Journal of hepatology 53, 608-615, https://doi.org/10.1016/j.jhep.2010.04.020 (2010).
22. Dwyer, K. M., et al. CD39 and control of cellular immune responses. Purinergic signalling 3, 171-180, https://doi.org/10.1007/s11302-006-9050-y (2007).
23. Zhou, A. Y. & Johnson, D. B. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. American journal of clinical dermatology, doi:https://doi.org/10.1007/s40257-017-0320-y (2017).
24. Burotto, M., Chiou, V. L., Lee, J. M. & Kohn, E. C. The MAPK pathway across different malignancies: A new perspective. Cancer 120, 3446-3456, https://doi.org/10.1002/cncr.28864 (2014).
25. Zhenzhong, Z., Yafa, Y. & Jin, L. Fibrinogen-like protein 2 gene silencing inhibits cardiomyocytes apoptosis, improves heart function of streptozotocin-induced diabetes rats and the molecular mechanism involved. Bioscience reports 35, doi:https://doi.org/10.1042/BSR20150078 (2015).
26. Tsimafeyeu, I. V., Demidov, L. V., Madzhuga, A. V., Somonova, O. V. & Yelizarova, A. L. Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Journal of experimental & clinical cancer research: CR 28, 30, https://doi. org/10.1186/1756-9966-28-30 (2009).
27. Erdem, S., et al. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics. Urologic oncology 32, 1031-1040, https://doi.org/10.1016/j. urolonc.2014.03.013 (2014).
28. Rickles, F. R., Patierno, S. & Fernandez, P. M. Tissue factor, thrombin, and cancer. Chest 124, 58S-68S (2003).
29. Versteeg, H. H., Peppelenbosch, M. P. & Spek, C. A. Tissue factor signal transduction in angiogenesis. Carcinogenesis 24, 1009-1013, https://doi.org/10.1093/carcin/bgg039 (2003).
30. Su, G., et al. Fibrinogen-like protein 2 expression correlates with microthrombosis in rats with type 2 diabetic nephropathy. Journal of Biomedical Research 25, 120-127, https://doi.org/10.1016/s1674-8301(11)60015-8 (2011).
31. Su, K. Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-?. World journal of gastroenterology 14, 5980, https://doi.org/10.3748/wjg.14.5980 (2008).
32. Kim, S. P., et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: Results from a large, single institution cohort. The Journal of urology 185, 2035-2039, https://doi.org/10.1016/j. juro.2011.02.059 (2011).
33. Arya, M., et al. Basic principles of real-time quantitative PCR. Expert review of molecular diagnostics 5, 209-219, https://doi. org/10.1586/14737159.5.2.209 (2005).
34. Xu, L., et al. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Annals of surgical oncology 21, 3142-3150, https://doi.org/10.1245/s10434-014-3601-1 (2014).
35. Li, J., et al. Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NFkappaB signaling. Oncogene. https://doi.org/10.1038/onc.2016.90 (2016).